Claudia Milbradt is a partner at Clifford Chance and has worked there since 1999. She specialises her practice in patent litigation, and has represented clients in the medical devices industry. Her notable cases include representing a German biotechnology company in negotiations on research and development and patent licensing agreements, as well as advising a leading medical devices company on a know.how infringement claim. Milbradt is fluent in English.
In the last 12 months, besides successful patent litigations for Strix, Hyuandai and B.Braun Medical and strategic patent advice for many different clients, Claudia and her team advised on many very high profile IP driven transactions such as the acquisition of Osram's lamp business for MLS, acquisition of Merck KGaA's biosimilars business for Fresenius Kabi, sale of Acino's transdermal patch and implant business, Denka concerning the acquisition of the biothech company Icon Genetics and Adiuva Capital on the sale of the GBA group- one of the leading providers of laboratory services in German.
Clients have described Claudia as "very experienced, realistic, prepares excellently for court appointments and fights for her client while remaining objective and proper."
Global Intellectual Property Newsletter - 16th Issue - IP at the interface of antitrust and questions related to ownership in data
December 2017 http://bit.ly/CCIPNL
Landmark decisions on FRAND licensing in Germany: What to look out for in negotiations, September 2017
Member of the German Society for Intellectual Property (GRUR)